Form 4: Fulcrum Therapeutics Officer Sells Shares to Cover Tax Obligations

Gregory Tourangeau, Principal Accounting Officer of Fulcrum Therapeutics, sold 498 shares of common stock on May 8, 2025, to cover tax withholding obligations related to vesting restricted stock units.

Summary

• On May 8, 2025, Gregory Tourangeau, the Principal Accounting Officer of Fulcrum Therapeutics, sold 498 shares of the company's common stock.
• The sale was executed at a price of $5.06 per share.
• This transaction was conducted to cover tax withholding obligations associated with the vesting of restricted stock units.
• Following the transaction, Tourangeau beneficially owns 14,062 shares of Fulcrum Therapeutics.
• This includes 2,989 shares acquired under the Issuer's employee stock purchase plan on May 14, 2024.

Sentiment

Score: 5

Explanation: The document describes a routine transaction (sale of shares to cover taxes) and doesn't contain any information that would significantly impact investor sentiment positively or negatively.

Industry Context

Form 4 filings are a routine part of the US stock market, providing transparency into the transactions of company insiders. This particular filing indicates a sale of shares to cover tax obligations, which is a common practice.

Stakeholder Impact

• The sale of shares by an officer could have a minor impact on shareholder sentiment, but is unlikely to be significant given the reason for the sale (tax obligations).

Key Dates

Keywords

Form 4, Fulcrum Therapeutics, FULC, Gregory Tourangeau, stock sale, tax withholding, restricted stock units, beneficial ownership, employee stock purchase plan